Verrica Pharmaceuticals (VRCA) Common Equity (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Common Equity of $16.1 million for Q1 2026, up 186.43% year-over-year from $5.6 million in Q1 2025, and down 35.11% quarter-over-quarter from $24.7 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Common Equity (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Common Equity history runs 10 years deep, the most recent figure standing at $16.1 million for Q1 2026.
- In Q1 2026, Common Equity rose 186.43% year-over-year to $16.1 million; the TTM figure through Mar 2026 stood at $16.1 million (up 186.43% YoY), while the FY2025 annual figure was $24.7 million, up 350.94% from the prior year.
- Common Equity for Q1 2026 stood at $16.1 million, down from $24.7 million in the prior quarter.
- The five-year high for Common Equity was $64.8 million in Q1 2023, with the low at -$34.1 million in Q3 2024.
- The 5-year median for Common Equity is $16.3 million (2022), against an average of $14.2 million.
- Peak annual rise in Common Equity reached 350.94% in 2025, while the deepest fall reached 1331.83% in 2025.
- Verrica Pharmaceuticals' Common Equity stood at $40.0 million in 2022, then slumped by 50.63% to $19.8 million in 2023, then plunged by 149.89% to -$9.9 million in 2024, then jumped by 350.94% to $24.7 million in 2025, then tumbled by 35.11% to $16.1 million in 2026.
- Business Quant data shows VRCA's Common Equity at $16.1 million in Q1 2026, $24.7 million in Q4 2025, and -$17.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 9.79 Bn |
| 10 | Verrica Pharmaceuticals | 106.31 Mn | 95.11 Mn | - | 4.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.31 Mn |
| Mar 31, 2026 | 16.06 Mn |
| Dec 31, 2025 | 24.74 Mn |
| Sep 30, 2025 | -17.04 Mn |
| Jun 30, 2025 | -17.48 Mn |
| Mar 31, 2025 | -18.58 Mn |
| Dec 31, 2024 | -9.86 Mn |
| Sep 30, 2024 | -34.05 Mn |
| Jun 30, 2024 | -13.30 Mn |
| Mar 31, 2024 | 1.51 Mn |
| Dec 31, 2023 | 19.76 Mn |
| Sep 30, 2023 | 42.30 Mn |
| Jun 30, 2023 | 55.40 Mn |
| Mar 31, 2023 | 64.85 Mn |
| Dec 31, 2022 | 40.03 Mn |
| Sep 30, 2022 | 44.77 Mn |
| Jun 30, 2022 | 16.33 Mn |
| Mar 31, 2022 | 25.42 Mn |
| Dec 31, 2021 | 32.61 Mn |
| Sep 30, 2021 | 40.85 Mn |